Original Research Online Published: 29 Sep 2021 | ||||||||||||
A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma Dibyendu Chakraborty, Chiranjib Bagchi, Santanu Kumar Tripathi.
|
How to Cite this Article |
Pubmed Style Chakraborty D, Bagchi C, Tripathi SK. A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma. Natl J Physiol Pharm Pharmacol. 2022; 12(3): 336-342. doi:10.5455/njppp.2022.12.09321202114092021 Web Style Chakraborty D, Bagchi C, Tripathi SK. A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma. https://www.njppp.com/?mno=119901 [Access: February 07, 2025]. doi:10.5455/njppp.2022.12.09321202114092021 AMA (American Medical Association) Style Chakraborty D, Bagchi C, Tripathi SK. A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma. Natl J Physiol Pharm Pharmacol. 2022; 12(3): 336-342. doi:10.5455/njppp.2022.12.09321202114092021 Vancouver/ICMJE Style Chakraborty D, Bagchi C, Tripathi SK. A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma. Natl J Physiol Pharm Pharmacol. (2022), [cited February 07, 2025]; 12(3): 336-342. doi:10.5455/njppp.2022.12.09321202114092021 Harvard Style Chakraborty, D., Bagchi, . C. & Tripathi, . S. K. (2022) A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma. Natl J Physiol Pharm Pharmacol, 12 (3), 336-342. doi:10.5455/njppp.2022.12.09321202114092021 Turabian Style Chakraborty, Dibyendu, Chiranjib Bagchi, and Santanu Kumar Tripathi. 2022. A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma. National Journal of Physiology, Pharmacy and Pharmacology, 12 (3), 336-342. doi:10.5455/njppp.2022.12.09321202114092021 Chicago Style Chakraborty, Dibyendu, Chiranjib Bagchi, and Santanu Kumar Tripathi. "A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 336-342. doi:10.5455/njppp.2022.12.09321202114092021 MLA (The Modern Language Association) Style Chakraborty, Dibyendu, Chiranjib Bagchi, and Santanu Kumar Tripathi. "A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma." National Journal of Physiology, Pharmacy and Pharmacology 12.3 (2022), 336-342. Print. doi:10.5455/njppp.2022.12.09321202114092021 APA (American Psychological Association) Style Chakraborty, D., Bagchi, . C. & Tripathi, . S. K. (2022) A comparative study of timolol plus either brimonidine (0.2%) or dorzolamide (2%) or latanoprost (0.005%) dual therapy in suboptimal responders to timolol (0.5%) monotherapy among patients of open-angle glaucoma, ocular hypertension and normal-tension glaucoma. National Journal of Physiology, Pharmacy and Pharmacology, 12 (3), 336-342. doi:10.5455/njppp.2022.12.09321202114092021 |